The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer

Single Agent Chemotherapy With Weekly Docetaxel vs Combination Chemotherapy in Second-line Treatment of Advanced Non Small Cell Lung Cancer

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00345059

Acronym

DISTAL-2

Enrollment

Registered

2006-06-27

Start date

2005-05-31

Completion date

2008-05-31

Last updated

2016-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Non-Small Cell Lung Cancer

Keywords

second line, monochemotherapy, combination chemotherapy, platinum refractory, previously treated

Brief summary

The purpose of this study is to compare the overall survival of patients with advanced non small cell lung cancer treated with docetaxel as single therapy versus docetaxel in combination with either gemcitabine or vinorelbine or in combination with capecitabine.

Detailed description

This study is for patients with previously diagnosed advanced non small cell lung cancer (NSCLC, stage IIIb or IV) who had progression of their disease during or after first-line therapy containing platinum. Patients will be assigned to receive 6 cycles of therapy from one of four treatment regimens: * docetaxel * docetaxel + vinorelbine * docetaxel + gemcitabine * docetaxel + capecitabine

Interventions

DRUGdocetaxel

DRUGvinorelbine

DRUGgemcitabine

DRUGcapecitabine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 75 Years

Healthy volunteers

Inclusion criteria

* Written informed consent * Age \> 18 * Histological diagnosis of non small-cell lung cancer (NSCLC) * Stage IIIb or Stage IV disease (in IIIb, previous treatment with chemotherapy + radiotherapy, or metastatic supraclavicular lymph nodes or pleural effusion) * Disease in progression * Previous chemotherapy with platinum-derivative (and with \> 21 days from last administration)

Exclusion criteria

* ECOG performance status \> 2 * Age \> 75 years * History of malignant neoplasm within the previous 5 years (except for baso- or spino-cellular skin carcinoma and in-situ carcinoma of the uterine cervix, provided they are being adequately treated) * Previous treatment with docetaxel * Presence of symptomatic cerebral metastasis * Neutrophils \< 2.0 x 109/l, platelets \< 100,000/l, hemoglobin \> 10g/dl * Bilirubin \< 1.5 x the upper normal limit * SGOT , SGPT, or bilirubin \> 1.25 x the upper normal limits except in the presence of hepatic metastasis * Creatinine \>1.25 x the upper normal limit * Any concomitant pathology that would, in the Investigator's opinion, contraindicate the use of the drugs in the protocol * Inability to comply with follow up * Pregnant or nursing females

Design outcomes

Primary

Measure	Time frame
overall survival	one year

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 5, 2026